Accueil Ernstrade Bourse Actualite Stock



Alchemia Limited is a biotechnology company. The Company is engaged in developing human therapeutics-based on its drug discovery, dry targeting and synthesis technologies. The Company has two late stage assets in generic fondaparinux and HA-Irinotecan. Generic Fondaparinux asset is fondaparinux sodium for injection, a generic version of the anti-coagulant drug sold under the brand name Arixtra by GlaxoSmithKline. The Hyaluronic Acid Chemotransport Technology platform (HyACT) utilizes Hyaluronic Acid to improve the delivery of chemotherapeutic agents to cancer cells and boost drug efficacy without increasing adverse side effects. Alchemia Inc. and Alchemia Oncology Pty Ltd are the subsidiaries of the Company.
Brisbane Technology Park 3 Hi-Tech Court
Eight Mile Plains, QLD 4113
+61-7-33400200 (Phone)
+61-7-33400222 (Fax)




Copyright  2011